On this page
Overview
Product & regulatory status
Foundayo is FDA-approved; approval applies to the finished product and labeled indication.
A nonpeptide GLP-1 agonist
Orforglipron stimulates the GLP-1 receptor through a small molecule rather than a peptide. Oral delivery does not remove systemic risks. [1]
What the evidence shows
Clinical trial evidence
ATTAIN-1 was a 72-week randomized, placebo-controlled trial alongside diet and physical activity. Orforglipron produced greater weight reduction than placebo in adults with obesity. [2]
Current U.S. indication
FDA’s approval covers weight reduction and maintenance in adults with obesity or overweight with at least one weight-related condition, together with nutrition and activity measures. [3]
What remains unknown
Approval for this indication does not establish every proposed use of GLP-1 medicines, and a research powder is not the approved tablet.
Safety
Safety and interactions
The label includes MTC/MEN2 contraindications, pancreatitis and gastrointestinal warnings, dehydration-related kidney injury, and interaction precautions involving CYP3A4 medicines, simvastatin, and oral contraceptives. A pharmacist should review the full list. [1]
Approved oral formulation
Foundayo is supplied as tablets. Its label contains product-specific handling, administration, and interaction information. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [4]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [5]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Are trial amounts interchangeable with marketed tablets?
Do not infer an equivalent amount from an older study. The label explains that trial and marketed formulations differ; use the prescribed product instructions.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- FOUNDAYO (orforglipron) prescribing informationFDA · Revised July 2026
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment2025 · Primary research · PubMed
- FDA Approves First New Molecular Entity Under National Priority Voucher ProgramFDA · April 1, 2026 · Foundayo approval
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.